等待開盤 01-29 09:30:00 美东时间
0.000
0.00%
Oppenheimer started coverage of Q32 Bio (NASDAQ:QTTB) with an outperform rating, citing the market potential of the company’s lead drug asset, bempikibart. The investment bank said it sees significant...
2024-04-12 00:55
Q32 Bio (NASDAQ:QTTB) said it has appointed Lee Kalowski as CFO and president. Kalowski brings over two decades of biopharmaceutical experience with a focus on strategy, raising capital, and financial...
2024-04-03 19:26
BEDFORD, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Homology Medicin...
2024-03-19 04:30
NEW YORK, Feb. 27, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or...
2024-02-28 09:52
NEW YORK, Nov. 20, 2023 /PRNewswire/ -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities...
2023-11-21 09:29
Gainers LumiraDx (NASDAQ:LMDX) shares rose 42.8% to $0.14 during Thursday's re...
2023-11-17 01:31
--The combined company will operate as Q32 Bio Inc., advancing the development of Q32 Bio's two clinical development candidates, bempikibart (ADX-914) in Phase 2 for the treatment of atopic ...
2023-11-16 20:05
生物技术赛道来到了多事之秋。 铅笔道前阵子刚写过,总部位于新加坡的生物技术创业公司Tessa由于无法筹集额外资金或找到买家接盘,已于6月30日正式关闭。 就在本...
2023-08-07 09:27
Homology Medicines Inc (NASDAQ: FIXX) announced initial data from the first dose cohort in the pheEDIT Phase 1 dose-escalation trial evaluating gene editing candidate HMI-103 in adults with
2023-07-28 21:14
Gainers Reata Pharmaceuticals (NASDAQ:RETA) shares rose 52.2% to $165.24 durin...
2023-07-28 21:05